Sanofi (SNY.US) Consumer Health Department's battle is heating up, with lenders preparing over 10 billion euros in funds to support the acquisition.
Some core banks have signed financing commitments for priority debt of 7.5 billion to 7.8 billion euros over the weekend to support the bid for this acquisition. They will also provide a revolving credit line of approximately 1.2 billion euros.
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Sanofi:la Presidencia Polaca De La UE Allana El Camino Para Una Industria Farmacéutica Competitiva
Express News | I-mab and Sanofi have reached an authorization agreement, with a potential total price of up to 0.2 billion euros.
Sanofi's Market Advantage and Growth Trajectory: A Strong Buy Recommendation